These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2782323)

  • 1. Pharmacokinetics of rilmenidine.
    Genissel P; Bromet N
    Am J Med; 1989 Sep; 87(3C):18S-23S. PubMed ID: 2782323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of rilmenidine in healthy subjects.
    Genissel P; Bromet N; Fourtillan JB; Mignot A; Albin H
    Am J Cardiol; 1988 Feb; 61(7):47D-53D. PubMed ID: 2894158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of rilmenidine.
    Singlas E; Ehrhardt JD; Zech P; Pozet N; Genissel P
    Am J Cardiol; 1988 Feb; 61(7):54D-59D. PubMed ID: 2894159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of rilmenidine in patients with chronic renal insufficiency and in hemodialysis patients.
    Aparicio M; Dratwa M; el Esper N; Fillastre JP; Levaltier B; Lins R; Meyrier A; Mignon F; Ryckelynck JP; Sennesael J
    Am J Cardiol; 1994 Dec; 74(13):43A-50A. PubMed ID: 7998585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioequivalence evaluation of rilmenidine in healthy volunteers.
    Groenewoud G; Potgieter L; Meyer B
    Arzneimittelforschung; 2009; 59(5):233-7. PubMed ID: 19537523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic treatment with rilmenidine in spontaneously hypertensive rats: differences between two schedules of administration.
    Monassier L; Greney H; Thomas L; Bousquet P
    J Cardiovasc Pharmacol; 2004 Mar; 43(3):394-401. PubMed ID: 15076223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Innovative Approach to Characterize Clinical ADME and Pharmacokinetics of the Inhaled Drug Nemiralisib Using an Intravenous Microtracer Combined with an Inhaled Dose and an Oral Radiolabel Dose in Healthy Male Subjects.
    Harrell AW; Wilson R; Man YL; Riddell K; Jarvis E; Young G; Chambers R; Crossman L; Georgiou A; Pereira A; Kenworthy D; Beaumont C; Marotti M; Wilkes D; Hessel EM; Fahy WA
    Drug Metab Dispos; 2019 Dec; 47(12):1457-1468. PubMed ID: 31649125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concentration-effect relationships of two infusion rates of the imidazoline antihypertensive agent rilmenidine for blood pressure and development of side-effects in healthy subjects.
    de Visser SJ; van Gerven JM; Schoemaker RC; Cohen AF
    Br J Clin Pharmacol; 2001 May; 51(5):423-8. PubMed ID: 11421999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuated renal response to moxonidine and rilmenidine in one kidney-one clip hypertensive rats.
    Li P; Penner SB; Smyth DD
    Br J Pharmacol; 1994 May; 112(1):200-6. PubMed ID: 8032642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The bioavailability and pharmacokinetics of guanfacine after oral and intravenous administration to healthy volunteers.
    Carchman SH; Crowe JT; Wright GJ
    J Clin Pharmacol; 1987 Oct; 27(10):762-7. PubMed ID: 3323255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acceptability of rilmenidine and long-term surveillance of plasma concentrations in hypertensive patients with renal insufficiency.
    Lins RL; Daelemans R; Dratwa M; Verbeelen D; Sennesael J; Brisgand B; Lameire N
    Am J Med; 1989 Sep; 87(3C):41S-45S. PubMed ID: 2782326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly.
    Prichard BN; Graham BR
    Drugs Aging; 2000 Aug; 17(2):133-59. PubMed ID: 10984201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced hemodynamic responses to physical and mental stress under low-dose rilmenidine in healthy subjects.
    Teixeira de Castro RR; Tibiriçá E; de Oliveira MA; Moreira PB; Catelli MF; Rocha NN; Nóbrega AC
    Cardiovasc Drugs Ther; 2006 Apr; 20(2):129-34. PubMed ID: 16761192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Rilmenidine sympatholytic activity preserves mental and orthostatic sympathetic response and epinephrine secretion].
    Esler M; Lux A; Jennings G; Hastings J; Socratous F; Lambert G
    Arch Mal Coeur Vaiss; 2004; 97(7-8):786-92. PubMed ID: 15506067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of imidazoline-preferring receptors in regulation of sympathetic tone.
    Sannajust F; Head GA
    Am J Cardiol; 1994 Dec; 74(13):7A-19A. PubMed ID: 7998588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a fast LC-MS/MS method for quantification of rilmenidine in human serum: elucidation of fragmentation pathways by HRMS.
    Chytil L; Cvačka J; Marešová V; Štrauch B; Widimský J; Štícha M; Slanař O
    J Mass Spectrom; 2010 Oct; 45(10):1179-85. PubMed ID: 20815039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central I1-imidazoline receptors as targets of centrally acting antihypertensive drugs. Clinical pharmacology of moxonidine and rilmenidine.
    Van Zwieten PA; Peters SL
    Ann N Y Acad Sci; 1999 Jun; 881():420-9. PubMed ID: 10415946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Essential arterial hypertension treated with rilmenidin : what dose for what patient?].
    Amah G
    Presse Med; 1999 Jan; 28(1):11-6. PubMed ID: 9951504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rilmenidine: a novel approach to first-line treatment of hypertension.
    Laurent S; Safar M
    Am J Hypertens; 1992 Apr; 5(4 Pt 2):99S-105S. PubMed ID: 1350733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and tolerance of rilmenidine in patients with mild to moderate hypertension. Results of a Czech and Slovak 6-month multicenter study].
    Widimský J
    Vnitr Lek; 2002 Aug; 48(8):724-9. PubMed ID: 12425202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.